Dermatology Drugs Market Covering Acne; Dermatitis; Psoriasis; Other Drugs for Dermatology Diseases; Global Summary 2021: Covid 19 Impact and Recovery
The global dermatology drugs market grew from $26.37 billion in 2015 to $37.57 billion in 2020 at a CAGR of 7.33%. The global dermatology drugs market is expected to grow from $37.57 billion in 2020 to $62.82 billion in 2025 at a CAGR of 10.82%.
Dermatology Drugs Market Covering Acne; Dermatitis; Psoriasis; Other Drugs for Dermatology Diseases; Global Summary 2021: Covid 19 Impact and Recovery provides strategists, marketers and senior management with the critical information they need to assess the global dermatology drugs sector.
Reasons to Purchase
Fully updated for 2021 including the impact of the Covid 19/ Novel Coronavirus. Identify growth segments and opportunities. Facilitate decision making on the basis of historic and forecast data and key trends Develop strategies based on likely future developments. Gain a global perspective on the development of the market.Description
Dermatology Drugs Market Covering Acne; Dermatitis; Psoriasis; Other Drugs for Dermatology Diseases; Global Summary 2021: Covid 19 Impact and Recovery from the Business Research Company covers market characteristics, size and growth, segmentation, regional breakdowns, trends and strategies for this market.
The market characteristics section of the report defines and explains the market.
The market size section gives the dermatology drugs market revenues, covering both the historic growth of the market and forecasting the future.
Market segmentations break down the key sub sectors which make up the market. The regional breakdowns section gives the size of the market geographically.
The trends and strategies section highlights the likely future developments in the dermatology drugs market and suggests approaches.
Scope
Markets Covered: Acne; Dermatitis; Psoriasis; Other Drugs for Dermatology Diseases
Companies Mentioned: Galderma S.A.; Reckitt Benckiser Group plc; LEO Pharma A/S; Bayer AG; GlaxosmithKline
Geographic scope: Asia Pacific, North America, Western Europe, Eastern Europe, South America, Middle East, Africa
Countries: Australia, China, Hong Kong, India, Indonesia, Japan, South Korea, Malaysia, New Zealand, Philippines, Singapore, Thailand, Vietnam, Canada, USA, Mexico, Argentina, Brazil, Chile, Colombia, Peru, Venezuela, Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK, Czech Republic, Poland, Romania, Russia, Israel, Saudi Arabia, Turkey, UAE, Egypt, Nigeria, South Africa
Time series: Five years historic and forecast
Data: Market value in $ billions.
Data segmentations: Regional breakdowns, key sub segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.